Sam Salek

ORCID: 0000-0002-4612-5699
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Health Systems, Economic Evaluations, Quality of Life
  • Pharmaceutical Economics and Policy
  • Dermatology and Skin Diseases
  • Psoriasis: Treatment and Pathogenesis
  • Childhood Cancer Survivors' Quality of Life
  • Patient-Provider Communication in Healthcare
  • Cancer survivorship and care
  • Pharmaceutical Practices and Patient Outcomes
  • Pharmaceutical industry and healthcare
  • Palliative Care and End-of-Life Issues
  • Biosimilars and Bioanalytical Methods
  • Pharmaceutical Quality and Counterfeiting
  • Pharmaceutical studies and practices
  • Family Support in Illness
  • Allergic Rhinitis and Sensitization
  • Pharmacovigilance and Adverse Drug Reactions
  • Medicine and Dermatology Studies History
  • Sympathectomy and Hyperhidrosis Treatments
  • Economic and Financial Impacts of Cancer
  • Lysosomal Storage Disorders Research
  • Body Image and Dysmorphia Studies
  • Medical Malpractice and Liability Issues
  • Healthcare Policy and Management
  • Asthma and respiratory diseases
  • Acute Lymphoblastic Leukemia research

University of Hertfordshire
2016-2025

Institute of Economic Development
2017-2024

Centre for Innovation in Regulatory Science
2016-2024

Rutgers, The State University of New Jersey
2024

Swansea University
2022-2024

PharmaTrain Federation
2024

Cardiff University
2007-2023

Cardiff and Vale University Health Board
2023

Canadian Agency for Drugs and Technologies in Health
2016

Johns Hopkins University
2015

The contribution of psychological disorders to the burden skin disease has been poorly explored, and this is a large-scale study ascertain association between depression, anxiety, suicidal ideation with various dermatological diagnoses. This international multicenter observational cross-sectional was conducted in 13 European countries. In each dermatology clinic, 250 consecutive adult out-patients were recruited complete questionnaire, reporting socio-demographic information, negative life...

10.1038/jid.2014.530 article EN cc-by-nc-nd Journal of Investigative Dermatology 2014-12-18

<b><i>Aims:</i></b> To determine the minimal clinically important difference (MCID) of Dermatology Life Quality Index (DLQI) and its responsiveness to change in inflammatory skin diseases. <b><i>Methods:</i></b> A longitudinal study: at stage 1, patients completed DLQI a disease severity global question; 2, rating quality life (QoL; Global Rating Change Questionnaire, GRCQ) was added used as an anchor measure MCID DLQI....

10.1159/000365390 article EN Dermatology 2015-01-01

This study aimed to measure the impact of COVID-19 on quality life (QoL) survivors and their partners family members.A prospective cross-sectional global online survey using social media.Patients with or members (age ≥18 years).Online from June August 2020.The EuroQol group five dimensions three level (EQ-5D-3L) QoL COVID-19, Family Reported Outcome Measure (FROM-16) assess partner/family member's QoL.The was completed by 735 (mean age=48 years; females=563) at a mean 12.8 weeks after...

10.1136/bmjopen-2020-047680 article EN cc-by-nc-nd BMJ Open 2021-05-01

A prospective cross-sectional questionnaire study of 32 patients with psoriasis was carried out in order to validate the use Sickness Impact Profile (SIP) and compare its sensitivity Psoriasis Disability Index (PDI). Overall PDI scores, but not overall SIP correlated well PASI scores (P<0·05). There good correlation between (P<0·01). Psychosocial factors are more severely impaired than physical activities psoriasis. It is now possible directly disability experienced by psoriatic that...

10.1111/j.1365-2133.1990.tb04192.x article EN British Journal of Dermatology 1990-12-01

A multicentre, randomized, double-blind, controlled crossover clinical trial was conducted on 33 patients with severe refractory atopic dermatitis, to determine the effects of cyclosporin (5 mg/kg/day) their health-related quality life. Treatments were administered for 8-week periods. One group (n = 16) received placebo followed by cyclosporin, and other 17) then placebo. Health-related life assessed at 0, 8 16 weeks using a general measure, United Kingdom Sickness Impact Profile (UKSIP), an...

10.1111/j.1365-2133.1993.tb03170.x article EN British Journal of Dermatology 1993-10-01

Generic instruments measuring health‐related quality of life (HRQoL), like EQ5D™, enable comparison skin diseases with healthy populations and nondermatological medical conditions, as well calculation utility data. To measure HRQoL in patients common controls across Europe using the EQ5D. This multicentre observational cross‐sectional study was conducted 13 European countries. Each dermatology clinic recruited at least 250 consecutive adult outpatients to complete questionnaires, including...

10.1111/bjd.15280 article EN British Journal of Dermatology 2016-12-29

Skin conditions may have a strong impact on patients' sexual life, and thus influence personal relationships. Sexual issues are difficult to discuss directly in clinical practice, mediated instrument be useful capture such information. In this study item 9 of the Dermatology Life Quality Index was used collect information several skin 13 European countries. Among 3,485 patients, 23.1% reported problems. The impairment particularly high patients with hidradenitis suppurativa, prurigo,...

10.2340/00015555-2561 article EN cc-by-nc Acta Dermato Venereologica 2016-11-07

Aim Khat chewing is a common habit in Yemen and east African countries. Millions of people chew khat leaves daily for its euphoric energetic effects to increase alertness. Cathinone, the main active substance fresh leaves, has sympathomimetic which heart rate blood pressure. The aim was examine hypothesis that risk factor acute myocardial infarction (AMI) using hospital‐based matched case‐control study. Method Between 1997 1999, we selected 100 patients admitted Al‐Thawra teaching hospital...

10.1111/j.1365-2125.2005.02358.x article EN British Journal of Clinical Pharmacology 2005-03-02

One of the most important uses benefit-risk assessment pertains to approval new medicines by regulatory authorities and subsequent review these products during their life-cycle when safety and/or efficacy data becomes available. At present, there exist no validated, well-accepted models for that have appropriate degree sophistication, as a consequence are widely used or industry. The aim study was therefore develop model using multi-criteria decision analysis (MCDA).The MCDA methodology...

10.1002/pds.1435 article EN Pharmacoepidemiology and Drug Safety 2007-01-01

An understanding of the daily life impacts hyperhidrosis and how patients deal with them, based on qualitative research, is lacking. This study investigated impact using a mix research methods.Participants were recruited through patient support groups such as Hyperhidrosis Support Group UK. Data collected focus groups, interviews online surveys. A grounded theory approach was used in analysis data transcripts. from 71 participants, out an initial 100 individuals recruited.Seventeen major...

10.1186/s12955-017-0693-x article EN cc-by Health and Quality of Life Outcomes 2017-06-08

Introduction: In Europe and beyond, the rising costs of healthcare limited resources have resulted in implementation health technology assessment (HTA) to inform policy reimbursement decision-making. European legislation has provided a harmonized route for regulatory process with Medicines Agency, but decision-making still remains responsibility each country. There is recognized need move toward more objective collaborative environment new medicines Europe. Therefore, aim this study was...

10.3389/fphar.2017.00384 article EN cc-by Frontiers in Pharmacology 2017-06-30
Coming Soon ...